Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.
The purpose-built space in the city centre site offers strong growth potential for the business and is located close to Newcastle Upon Tyne Hospitals NHS Foundation Trust and Newcastle University, where the scientific co-founders have a significant academic group at the university…
Agreement to harness TTP’s industry expertise to assess the potential of emerging healthcare technologies and academic research
Cambridge, UK, 22nd June 2020: TTP plc (TTP), a leading independent technology and product development company, today announced that it has entered into a technology advisory partnership with Cancer Research UK. TTP has been selected by Cancer Research UK to apply its technology design and development expertise and insight in the healthcare sector, to assess discoveries made by the charity’s academic researchers.
Under the terms of the agreement, TTP…
AMSBIO has launched a range of ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads that combine convenience, minimum non-specific binding and developed operational protocols saving you time and hassle.Developed for immunocapture, cell stimulating, biopanning and flow cytometry applications these new products use biotinylated SARS-CoV-2 Spike protein pre-coupled to streptavidin conjugated magnetic beads, which can capture the Anti-SARS-CoV-2 antibody or ACE2 protein from cell or serum sample. Because Streptavidin has an extraordinarily high affinity for biotin with a dissociation…
The AMR Centre has combined forces to attract much needed investment to combat the global threat of antimicrobial resistance (AMR) resulting in a successful bid for a £114 million project supported by UK Research and Innovation (UKRI). The funding was secured by a North West UK based consortium that will work in partnership to create an integrated platform for the development of new treatments and diagnostics for infectious diseases.
Developed by UKRI, the Strength in Places Fund (SIPF) is a competitive funding scheme that takes a place-based approach to research and innovation to support…
As part of the agreement, Biocair will transport selected blood samples to specialist laboratories for investigation to find out if the individual has developed antibodies against the SARS-CoV-2 virus.
The Bundesliga was the first European football league to restart amidst the ongoing pandemic. As a result, the league has implemented several protective measures to guard staff and players against COVID-19. This includes mandatory testing across all clubs.
Miguel Rodriguez, Client Relationship Manager at Biocair GmbH, comments:
“It is a great honour to be able to provide logistical support to…
Start Codon aims to rapidly translate the most disruptive and innovative life science research into successful companies and positive clinical outcomes
The first cohort of four companies will debut at the Milner Therapeutics Symposium on the 26th June and at OnHelix on the 14th July
Start Codon is now accepting applications for its second cohort of companies. Early stage start-up companies in the life sciences and healthcare space are invited to apply via https://startcodon.co/application-form
CAMBRIDGE UK, 22 June 2020 – Start Codon, a new model of life science and healthcare business…
June 23, 2020 02:01 AM Eastern Daylight Time
SAN DIEGO-Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. Three companies comprise the inaugural funding cycle of Illumina Accelerator Cambridge, UK and four companies will join as part of the 11th funding cycle in the San Francisco Bay Area. Due to lockdowns and travel restrictions during the current COVID-19 pandemic, Illumina Accelerator kicked off both…
Dr Steven Newhouse is the Head of Technical Services at EMBL's European Bioinformatics Institute (EMBL-EBI). He has previously held roles in the leadership of European Grid Infrastructure activities and was a Program Manager in the High Performance Computing (HPC) group in the Windows server division at Microsoft. Dr Newhouse’s role today involves managing teams that bring both new innovations and established technology services from Europe and around the world to further develop and support the life sciences.
Part of the European Molecular Biology Laboratory, EMBL-EBI helps scientists…
- Experienced tech leader Meri Williams joins Healx - the AI-powered, patient-inspired technology company - from challenger bank Monzo, as Chief Technology Officer.
- In her new role, Meri will focus on scaling Healx’s technology and team following their successful Series B raise of $56 million in October 2019.
- Meri’s appointment consolidates Healx’s focus on technical excellence, and is the latest in several senior appointments at Healx over the last few months.
Cambridge, UK - 17 June, 2020. Healx, the AI-powered, patient-inspired technology company accelerating the discovery and…
NORWICH, UK - 17 June 2020: Leaf Expression Systems (Leaf), a contract development and manufacturing organisation based in Norwich, UK, has announced today that it has developed a recombinant SARS-CoV-2 N-protein (antigen) to aid research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) pandemic.
The recombinant SARS-CoV-2 N-protein consists of the full-length Nucleocapsid protein (N-Protein) from SARS-Cov-2, appended with a His-Tag. The N-protein performs vital functions during the viral lifecycle of SARS-Cov-2; including binding and packaging of viral genomic RNA during replication and…